The increased income was driven by revenues and gross margin increases as a result of the company’s direct operation transitions and international markets. Research and development expenses increased 18 percent to $2.1 million, prompting a 29 percent increase in operating profit.
The company’s knee implant revenue increased 1 percent to $21.5 million while the revenue from extremities and hip business lines both increased 37 percent. Conversely, the company’s spine and biologic revenue decreased 13 percent to $6.2 million.
More Articles on Orthopedic Device Companies:
DJO Global Net Sales Jump 11.7%
Zimmer’s Q1 Hip & Knee Sales Up 2%, Spine Sales Drop
Orthofix Net Sales Reach $143.1M, Spine Sales Grow 3%
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.